We need a general tweet of the day thread

Fire_Marshall_Bill · March 25

https://twitter.com/choeshow/status/1903975689793216679

EverettChris · March 25

https://hardcorehusky.com/discussion/comment/2062298#Comment_2062298

Good luck, Oregon.

Fire_Marshall_Bill · March 25

https://twitter.com/MAGAVoice/status/1904604075762884921

PurpleThrobber · March 25

http://twitter.com/defense_civil25/status/1904503525624721593

Didn’t have literally Hitler on the dance card in March.

Didn’t say this is true either. Don’t twist.

WestlinnDuck · March 25

Not a lot of money in Vitamin D therapy. Just like Vitamin D as a chicom crud preventative was ignored by the US medical bureaucracy and the MSM. Not ignored was Ivermectin which was actively discouraged as a preventative and therapeutic and medical licenses threatened and condemned as horse paste.

https://medicalxpress.com/news/2025-03-highdose-vitamin-d-significantly-disease.html

High‑dose vitamin D significantly reduces disease activity in early multiple sclerosis onset, clinical trial finds

by Justin Jackson , Medical Xpress

Researchers from CHU Nîmes, Université Montpellier, and multiple MS centers in France have found that oral cholecalciferol in doses of 100,000 IU every two weeks significantly reduced disease activity in clinically isolated syndrome and early relapsing‑remitting multiple sclerosis.

The study is published in the journal JAMA.

Multiple sclerosis (MS) typically starts with an acute episode involving the central nervous system, such as optic neuritis (inflammation of the optic nerve), transverse myelitis (inflammation of the spinal cord), or brainstem syndromes. This combination of initial signs is termed a clinically isolated syndrome (CIS), although CIS does not always convert to MS.

The risk factors for relapse (conversion to clinically definite MS) include the presence of cerebrospinal fluid oligoclonal bands, a high number of T2‑weighted fluid‑attenuated inversion recovery lesions on brain MRI, and younger age at CIS onset.

Vitamin D deficiency is a risk factor for MS and is associated with disease activity, but prior supplementation trials have produced conflicting results. Given its immunomodulatory effects, vitamin D has mostly been tested as an add‑on therapy to interferon beta. The research team aimed to evaluate the safety and efficacy of vitamin D as monotherapy in recent CIS cases.